Clinical Trial Update: Immunogenicity and Safety Study of GSK's MenABCWY Vaccine in Healthy Adolescents and Adults Previously Primed With MenACWY Vaccine [Phase 3]

View source ↗

Summary

Phase 3 immunogenicity and safety results for GSK's MenABCWY meningococcal vaccine in healthy adolescents and adults previously primed with MenACWY.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningitis
• Meningococcal Disease

Drugs mentioned

• MenABCWY vaccine

Snippet

Sponsor: GlaxoSmithKline | Conditions: Meningitis, Meningococcal | Phase 3 | Status: COMPLETED | Results posted: 2024-07-03